Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 258

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Renal-Cell Carcinoma — Molecular Pathways and Therapies

Brugarolas, James · 2007 · New England Journal of Medicine

Abstract

Renal-cell carcinoma is among the most resistant of tumors to therapy. Until 2005, only a single treatment, high-dose interleukin-2, had been approved by the Food and Drug Administration (FDA) for the treatment of this disease. The approval was based on durable complete responses in 5% of patients with metastatic disease,1 but high-dose therapy with interleukin-2 is quite toxic, and in most patients its benefit is unclear.In this issue of the Journal, Motzer et al.2 and Escudier et al.3 report on the results of phase 3 trials of two oral, small-molecule kinase inhibitors, sunitinib malate and sorafenib, respectively. Both drugs . . .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejme068263

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 258

Metadata

Authors
Brugarolas, J.
Venue
New England Journal of Medicine
Published
2007-01-11
Volume
356
Issue
2
Pages
185-187
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2004809400
Cited by
258
References
12
FWCI
23.70
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.